BDRX
Biodexa PharmaceuticalsBDRX
BDRX
About: Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
Employees: 13
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
50% more funds holding
Funds holding: 4 [Q4 2024] → 6 (+2) [Q1 2025]
0% more ownership
Funds ownership: 0% [Q4 2024] → 0% (+0%) [Q1 2025]
4% less capital invested
Capital invested by funds: $29.3K [Q4 2024] → $28.1K (-$1.2K) [Q1 2025]
Research analyst outlook
We haven’t received any recent analyst ratings for BDRX.
Financial journalist opinion
Based on 5 articles about BDRX published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
Results of Annual General Meeting
June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, announces that at its Annual General Meeting held yesterday, all resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting can be found in the Notice of the Annual General Meeting on the Company's website at https://biodexapharma.com/investors/corporate-governance//#agms.
Neutral
GlobeNewsWire
1 week ago
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce the activation of the first clinical study site for its Serenta trial in patients with familial adenomatous polyposis (FAP). The trial, which is now enrolling, represents a significant milestone in the development of a potential new treatment option for FAP.
Neutral
GlobeNewsWire
2 weeks ago
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, is pleased to announce it has selected Serenta as the brand name for its upcoming phase 3 clinical study in familial adenomatous polyposis (FAP). In conjunction with this announcement, the company launched a dedicated website, www.serentatrial.com, to provide information and resources for patients, caregivers, and healthcare professionals.
Neutral
Accesswire
2 weeks ago
Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study
CARDIFF, UNITED KINGDOM / ACCESS Newswire / June 18, 2025 / When it comes to type 1 diabetes, treating this chronic condition can be difficult. After all, with this type of diabetes, the body's immune system attacks and destroys the beta cells that produce insulin.
Neutral
GlobeNewsWire
3 weeks ago
Result of General Meeting
June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces, announces that at its General Meeting held earlier today, all four resolutions put to the Company's shareholders were duly passed. The full text of, inter alia, the resolutions proposed and passed at the Annual General Meeting and General Meeting can be found in the Notice of the General Meeting on the Company's website at: https://biodexapharma.com/investors/corporate-governance/#agms.
Neutral
GlobeNewsWire
1 month ago
Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes
June 4, 2025 Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced the recruitment of the first patient in a Phase 2 study of tolimidone in Type 1 Diabetes (“T1D”). The study is an Investigator Initiated Trial (IIT) conducted by the University of Alberta Diabetes Institute.
Neutral
GlobeNewsWire
1 month ago
Shareholder Update
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced a brief update for shareholders. Financial position As of May 29, 2025, the Company had access to the following cash resources: $ millions Cash at bank 5.7 Cash in escrow for eRapa Phase 3 program 4.4 10.1 Undrawn CPRIT grant for eRapa Phase 3 program 11.9 Debt 0.5 The CPRIT grant, together with Company match means the eRapa Phase 3 program is substantially funded.
Neutral
GlobeNewsWire
1 month ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces a Notice of a General Meeting to be held at the Company's offices, 1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ on 11 June 2025 at 1.00pm was posted to shareholders today. The Board of Directors is proposing four resolutions: Ordinary Resolutions 1.
Neutral
GlobeNewsWire
1 month ago
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced its collaboration partner, Rapamycin Holdings, Inc. d/b/a Emtora Biosciences (“Emtora”) has been awarded an additional grant of $3.0 million from the Cancer Prevention & Research Institute of Texas (“CPRIT”). This award brings the total grant awarded by CPRIT to support the registrational Phase 3 program of eRapa in familial adenomatous polyposis (“FAP”) to $20.0 million.
Positive
Zacks Investment Research
1 month ago
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Biodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Charts implemented using Lightweight Charts™